Asprosin is positively associated with metabolic syndrome in hemodialysis patients: a cross-sectional study

References

• Saran R, Robinson B, Abbott KC, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):1–6.
   PubMedGoogle Scholar
• Koh ES, Do Han K, et al. Changes in metabolic syndrome status affect the incidence of end-stage renal disease in the general population: a nationwide cohort study. Sci Rep. 2021;11(1):1957.
   PubMed Web of Science ®Google Scholar
• Tsangalis G, Papaconstantinou S, Kosmadakis G, et al. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs. 2007;30(2):118–123.
   PubMed Web of Science ®Google Scholar
• AlShelleh S, AlAwwa I, Oweis A, et al. Prevalence of metabolic syndrome in dialysis and transplant patients. Diabetes Metab Syndr Obes. 2019;12:575–579.
   PubMed Web of Science ®Google Scholar
• Syukri M, Virnardo R, Salwani D, et al. The prevalence and associated factors of metabolic syndrome among patients with end-stage renal failure undergoing hemodialysis in Indonesia. Diabetes Metab Syndr. 2020;14(6):2069–2072.
   PubMed Web of Science ®Google Scholar
• Li E, Shan H, Chen L, et al. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab. 2019;30(2):319–328.e8.
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444–1453.
   PubMed Web of Science ®Google Scholar
• Yuan M, Li W, Zhu Y, et al. Asprosin: a novel player in metabolic diseases. Front Endocrinol. 2020;11:64.
   PubMed Web of Science ®Google Scholar
• Luís C, Fernandes R, Soares R, et al. A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomed J. 2020;5(6):e108.
   PubMedGoogle Scholar
• Ugur, K, Aydin, S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019;2019:2521096.
   PubMed Web of Science ®Google Scholar
• Wang, Y, Qu, H, Xiong, X, Qiu, Y. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and First-Phase insulin secretion. Mediators Inflamm. 2018;2018:9471583.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–188.
   PubMed Web of Science ®Google Scholar
• Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes. 2020;69(4):559–566.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–480.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–636.
   PubMed Web of Science ®Google Scholar
• Chang F-C, Lee M-C, Chiang C-K, et al. Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease. J Formos Med Assoc. 2021;120(12):2113–2119.
   PubMed Web of Science ®Google Scholar
• Alswat KA, Althobaiti A, Alsaadi K, et al. Prevalence of metabolic syndrome among the end-stage renal disease patients on hemodialysis. J Clin Med Res. 2017;9(8):687–694.
   PubMedGoogle Scholar
• Yang S-Y, Chiang C-K, Hsu S-P, et al. Metabolic syndrome predicts hospitalization in hemodialysis patients: a prospective Asian cohort study. Blood Purif. 2007;25(3):252–259.
   PubMed Web of Science ®Google Scholar
• Dimitrijevic Z, Jovanovic A, Cvetkovic M, et al. Associations of cardiovascular and all-cause mortality with metabolic syndrome in hemodialysis patients: a prospective single-center study. Medicina. 2019;55(10):694.
   PubMedGoogle Scholar
• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–579.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Lin T-A, Liu K-H, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes. 2019;43(5):1019–1025.
   Web of Science ®Google Scholar
• Wang M, Yin C, Wang L, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019;75(4):205–212.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang H, Ma X, et al. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2020;11(2):349–355.
   PubMed Web of Science ®Google Scholar
• Hong T, Li J-Y, Wang Y-D, et al. High serum asprosin levels are associated with presence of metabolic syndrome. Int J Endocrinol. 2021;2021:1–7.
   Web of Science ®Google Scholar
• Ugur K, Erman F, Turkoglu S, et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Sci. 2022;26(6):2124–2133.
   PubMed Web of Science ®Google Scholar
• Acara AC, Bolatkale M, Kızıloğlu İ, et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med. 2018;36(8):1504–1505.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu W, Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol. 2020;52(8):1517–1522.
   PubMed Web of Science ®Google Scholar
• Goodarzi G, Setayesh L, Fadaei R, et al. Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy. Mol Biol Rep. 2021;48(7):5443–5450.
   PubMed Web of Science ®Google Scholar
• Wang R, Lin P, Sun H, et al. Increased serum asprosin is correlated with diabetic nephropathy. Diabetol Metab Syndr. 2021;13(1):51.
   PubMed Web of Science ®Google Scholar
• Jung TW, Kim H-C, Kim HU, et al. Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234(11):20888–20899.
   PubMed Web of Science ®Google Scholar
• Lee T, Yun S, Jeong JH, et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104.
   PubMed Web of Science ®Google Scholar
• Li, X, Liao, M, Shen, R, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm. 2018;2018:7375294.
   PubMed Web of Science ®Google Scholar